1. Home
  2. TORO vs ARMP Comparison

TORO vs ARMP Comparison

Compare TORO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

N/A

Current Price

$4.41

Market Cap

198.4M

ML Signal

N/A

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$2.84

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TORO
ARMP
Founded
2022
N/A
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
199.7M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
TORO
ARMP
Price
$4.41
$2.84
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $17.50
AVG Volume (30 Days)
88.6K
★ 90.3K
Earning Date
12-04-2026
11-16-2026
Dividend Yield
★ 61.48%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$2.75
52 Week High
$8.50
$14.98

Technical Indicators

Market Signals
Indicator
TORO
ARMP
Relative Strength Index (RSI) 42.68 36.72
Support Level $3.49 $2.75
Resistance Level $5.30 $5.63
Average True Range (ATR) 0.36 0.36
MACD 0.08 0.02
Stochastic Oscillator 68.27 7.76

Price Performance

Historical Comparison
TORO
ARMP

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: